A new report found that the sizes of seed rounds and Series A financings for Massachusetts biotech startups are going in opposite directions, as funding slows for young companies with the “riskiest science.”
An article from
Dive Brief
//
Emerging biotech
A new report found that the sizes of seed rounds and Series A financings for Massachusetts biotech startups are going in opposite directions.
Though funding totals represented the highest first-half sum since the start of 2022, industry watchers are concerned that small…
The number of people working in Massachusetts’ biotech sector fell last year, for the first time since at least 2002. But 2026 is…
MassBio report shows MA biopharma jobs fell 3.1%, NIH awards dropped 6%, while China's drug pipeline grew 36% in 2025, alarming…
Biotech is dominating the (very) early 2026 deals market.
As Greater Boston’s biotech industry sheds jobs, three unlikely regions are showing promise as up-and-coming hubs.
Biotech megarounds rebounded in the first half of 2026, with 40 companies raising $100M+, up from 33 in the same period last year.
